BMRN
BioMarin Pharmaceutical Inc.
BMRN lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BMRN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Stable | |
| Weak |
BMRN's revenue is currently strong, and its cash flow is stable, but its profitability and balance sheet are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BMRN PE Valuation
BMRN has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BMRN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
BMRN has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BMRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.46 | — |
| Q3 2026 | -$0.08 | -103% |
| Q2 2026 | $0.39 | -88% |
| Q1 2026 | $1.39 | -49% |
| Q4 2025 | $1.80 | -19% |
| Q3 2025 | $2.67 | +61% |
| Q2 2025 | $3.38 | +156% |
| Q1 2025 | $2.70 | +155% |
| Q4 2024 | $2.21 | +154% |
BMRN has swung to a loss: it lost $0.08 per share over the past year, after a profit the year before.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BMRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +32% |
| Q2 2026 | $989.7M | +20% |
| Q1 2026 | $766.2M | +2.8% |
| Q4 2025 | $874.6M | +17% |
| Q3 2025 | $776.1M | +4.1% |
| Q2 2025 | $825.4M | +16% |
| Q1 2025 | $745.1M | +15% |
| Q4 2024 | $747.3M | +16% |
BMRN's revenue has grown year over year for 19 quarters in a row: $1B last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -8% | -2 points |
| Q2 2026 | 11% | -22 points |
| Q1 2026 | 17% | -13 points |
| Q4 2025 | -5.1% | -27 points |
| Q3 2025 | -6% | -21 points |
| Q2 2025 | 34% | +17 points |
| Q1 2025 | 30% | +16 points |
| Q4 2024 | 22% | +19 points |
BMRN's operating margin was −8% last quarter, down 2 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BMRN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over BMRN on profitability, with a higher operating margin.
BMRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $159.9M | -53% |
| Q2 2026 | $139.3M | -17% |
| Q1 2026 | $199.7M | +27% |
| Q4 2025 | $58.9M | -65% |
| Q3 2025 | $340.2M | +68% |
| Q2 2025 | $168.2M | +73% |
| Q1 2025 | $157.6M | +655% |
| Q4 2024 | $166.1M | +$167.5M |
BMRN still generates free cash flow, though less than at its 2025 peak: $558M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BMRN on cash flow, with more consistent year-over-year improvement.
BMRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -877K shares |
| 1 year | +0.8% | +1.6M shares |
| 3 years | +1.3% | +2.4M shares |
| 5 years | +5.7% | +10.4M shares |
| Available history | +8.1% | +14.6M shares |
BMRN has 194M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BMRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BMRN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 9.1x | High |
| Q2 2026 | 11.0x | High |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -2.7x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.6x | Net Cash |
BMRN's net debt is about 9.1 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BMRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.3 | Neutral |
| Stochastic | 24.3 | Neutral |
BMRN's weekly RSI is 45 (neutral) and its Stochastic is 24 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BMRN PE vs Healthcare Sector
| Metric | BMRN | Sector median | Relative |
|---|---|---|---|
| PE | 150x | 26x | 480% above |
| PE % | 67 | 29 | 38 pts above |
BMRN has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BMRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $56.8 | 0.1% below |
| 20 week MA | $60.5 | 6.3% below |
| 50 week MA | $58.2 | 2.6% below |
| 100 week MA | $59.0 | 3.9% below |
| 200 week MA | $73.1 | 22% below |
BMRN is in a downtrend: it's below all five of its weekly moving averages, and 22% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BMRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $85.6 | $88.7 | +3.6% |
| 2021 | $88.7 | $91.2 | +2.8% |
| 2022 | $91.2 | $104.3 | +14% |
| 2023 | $104.3 | $96.4 | -7.6% |
| 2024 | $96.4 | $66.9 | -31% |
| 2025 | $66.9 | $60.0 | -10% |
| 2026 YTD | $60.0 | $56.7 | -5.4% |
BMRN has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.